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SUMOylation of FOXP1 regulates 
transcriptional repression via CtBP1 
to drive dendritic morphogenesis
Daniel L. Rocca, Kevin A. Wilkinson & Jeremy M. Henley  
Forkhead Box P (FOXP) transcriptional repressors play a major role in brain development and their 
dysfunction leads to human cognitive disorders. However, little is known about how the activity of 
these proteins is regulated. Here, we show that FOXP1 SUMOylation at lysine 670 is required for 
recruiting the co-repressor CtBP1 and transcriptional repression. FOXP1 SUMOylation is tightly 
controlled by neuronal activity, in which synapse to nucleus signalling, mediated via NMDAR and L-type 
calcium channels, results in rapid FOXP1 deSUMOylation. Knockdown of FOXP1 in cultured cortical 
neurons stunts dendritic outgrowth and this phenotype cannot be rescued by replacement with a non-
SUMOylatable FOXP1-K670R mutant, indicating that SUMOylation of FOXP1 is essential for regulation 
of proper neuronal morphogenesis. These results suggest that activity-dependent SUMOylation of 
FOXP1 may be an important mediator of early cortical development and neuronal network formation in 
the brain.
Forkhead Box P (FOXP) proteins are a subfamily of transcription factors that bind to promoter and enhancer 
sequences in many genes via a forkhead DNA binding motif to spatially and temporally control the expression of 
a wide range of genes1. FOXP family members are involved in embryonic morphogenesis1 and they play key roles 
in regulating the development and differentiation of cells in many tissue types. Furthermore, mutations in FOXP 
proteins have been implicated in many human developmental disorders2 and their malfunction can cause severe 
cognitive disorders3, 4. In humans, there are four members of the FOXP family, FOXP1-4 and, of these, FOXP1, 
FOXP2 and FOXP4 are highly expressed in the CNS, and have each been implicated in cortical development, and 
motor learning3. Mutations in FOXP2 cause verbal dyspraxia in humans5 and its deletion reduces vocalisaion in 
mice and impairs song learning in songbirds6.
Interestingly, FOXP1 and FOXP2 can form heterodimers to regulate transcription and they overlap in their 
expression pattern in songbird and foetal human brain, suggesting that FOXP1 may also have a role in speech 
and language disorders7. Moreover, mutations in FOXP1 are associated with intellectual disability and autism 
spectrum disorder (ASD)8, 9 and FOXP1 knockout mice display developmental deficits and reduced social inter-
actions, similar to mouse models of autism10. Indeed, inhibition of Foxp1 expression in the mouse cortex impairs 
neuronal migration, polarisation and the maturation of dendritic processes10, 11. However, how FOXP1 is regu-
lated during early cortical development and the signals that initiate these processes remain unknown.
SUMOylation is a posttranslational modification that regulates the functions and fates of hundreds of proteins 
in nearly all cell pathways12 and in the brain it directly impacts on diverse aspects of neuronal morphology and 
function13. The consequences of SUMOylation are varied but the underlying principle is that it alters inter- and/or 
intramolecular interactions to change substrate protein localisation, stability, and/or activity. Furthermore, inap-
propriate regulation of the SUMO pathway is a common factor in many neurological and neurodegenerative dis-
eases13. Both FOXP1 and FOXP2 bind SUMO E3 ligases, and have been demonstrated to be SUMO substrates14. 
SUMOylation of cerebellar FOXP2 in mouse neonates modifies its transcriptional activity to regulate Purkinje 
cell development, dendritic outgrowth and arborization, and is required for correct cerebellar motor function and 
vocal communication15, 16.
Here we demonstrate that endogenous FOXP1 is SUMOylated at K670 in rat neurons and this is required 
for efficient transcriptional repression, likely by promoting binding to the transcriptional co-repressor CtBP1. 
FOXP1 SUMOylation is activity-dependently regulated via calcium entry through both NMDA receptors 
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(NMDARs) and L-type calcium channels. Ablation of FOXP1 in cultured cortical neurons dramatically stunts 
dendritic outgrowth and this phenotype can be rescued by expression of wild-type but not a non-SUMOylatable 
FOXP1-K670R mutant. Moreover, we show that FOXP1 SUMOylation is required for regulation of CNTNAP2 
expression, a candidate autism gene involved in dendritic maturation. Thus, FOXP1 SUMOylation is essential for 
the proper neuronal morphogenesis that ultimately is required for cortical development and neuronal network 
formation.
Results
FOXP1 is SUMOylated at K670. We initially determined if FOXP1 is a target for SUMOylation in neu-
rons by lysing primary cultured cortical neurons under either native or strong denaturing conditions (2% SDS) 
to prevent SUMO deconjugation by SUMO proteases. Western blots for FOXP1 displayed a very robust higher 
molecular weight species under denaturing conditions, with a band shift consistent with a SUMOylated form 
of the protein (Fig. 1A). To confirm that the higher molecular weight band constituted SUMOylated FOXP1 we 
immunoprecipitated FOXP1 and incubated the immunoprecipitate with active or inactive catalytic domains of 
the SUMO-specific protease Senp1. The higher molecular weight band was absent in the active Senp1 samples 
but present in the samples treated with the inactive point mutant (Senp1-C603S; Fig. 1B). Additionally, immu-
noprecipitation of SUMOylated proteins with SUMO1 antibody and immunoblotting for FOXP1 also detected a 
band corresponding to SUMOylated FOXP1 (Fig. 1C). These data confirm that FOXP1 is strongly SUMO1-ylated 
under basal conditions in cultured rat cortical neurons.
SUMOylation often occurs at lysines in the consensus sequence ΨKX(D/E)17, 18. Using a prediction algorithm 
(SUMOplot)19 we identified a single lysine (K670) as a high-confidence SUMOylation site (Fig. 1D). To determine 
if this is the SUMOylation site we cloned rat FOXP1-WT and a non-SUMOylatable mutant (FOXP1-K670R) into 
a tandem affinity purification (TAP) tagging vector. When expressed in HEK293T cells TAP-FOXP1-WT was 
robustly SUMOylated whereas there was no SUMOylation of TAP-FOXP1-K670R (Fig. 1E) indicating that lysine 
670 is the sole SUMOylation site in FOXP1.
SUMOylation of FOXP1 promotes transcriptional repression. We next tested how SUMOylation 
regulates FOXP1 function. The SV40 promoter is a well-characterised target for FOXP1 repression20 so we 
co-transfected HEK293T cells with a reporter plasmid containing an SV40-driven firefly luciferase together with 
either empty TAP vector, TAP-FOXP1-WT or TAP-FOXP1-K670R. TAP-FOXP1-WT reduced luciferase activity 
by ~80% whereas TAP-FOXP1-K670R did not significantly repress SV40-driven luciferase expression (Fig. 2A) 
demonstrating that SUMOylation is required for effective FOXP1 transcriptional repression.
SUMOylation does not regulate the localisation, stability or dimerization of 
FOXP1. SUMOylation often alters the localisation and/or stability of target proteins so we compared the 
nuclear localisation and total levels of TAP-FOXP1-WT or TAP-FOXP1-K670R. There was no difference between 
the nuclear and cytosolic localisation or total protein levels of WT and non-SUMOylatable FOXP1 in transfected 
HEK293T cells (Fig. 2B). Because FOXP proteins need to dimerise to be transcriptionally active21 we tested if 
SUMOylation is required for FOXP1 dimerisation. Both TAP-FOXP1-WT and TAP-FOXP1-K670R efficiently 
homodimersised with GFP-tagged FOXP1 (Fig. 2C) indicating that SUMOylation does not control nuclear par-
titioning, stability or dimerization of FOXP1.
SUMOylation of FOXP1 enhances binding to the co-repressor Ctbp1. A prime role of 
SUMOylation is to alter protein-protein interactions so we reasoned that SUMOylation could regulate protein 
complex assembly required for FOXP1 activity. To find novel FOXP1-interacting proteins we expressed either 
empty TAP vector or TAP-FOXP1-WT in HEK293T cells followed by pulldown on streptavidin beads and ana-
lysed proteins specifically retained by the TAP-FOXP1 matrix via mass spectrometry. We identified multiple 
binding proteins (Fig. 2D) and, of these, we focused on C-terminal-binding protein 1 (CtBP1)22, which is a tran-
scriptional co-repressor for FOXP proteins20.
We validated the proteomics data by confirming that FOXP1 and the known Ctbp1 co-repressor complex 
components histone lysine demethylase LSD123 and HDAC224 co-immunoprecipitated with Ctbp1, whereas the 
class IIa histone de-acetylase HDAC4, which is not normally associated with this complex, did not (Fig. 2E).
We then tested the effect of FOXP1 SUMOylation on recruitment of the Ctbp1 co-repressor complex using 
glutathione sepharose beads coupled to recombinant, bacterially-produced SUMOylated or non-SUMOylated 
FOXP125. Beads were incubated with neuronal lysates and blotted for Ctbp1 and the co-regulatory protein 
SMRT, a known FOXP1 interaction partner26. Intriguingly SMRT bound equally to both SUMOylated and 
non-SUMOylated FOXP1 whereas Ctbp1 binding to non-SUMOylated FOXP1 was dramatically diminished 
(Fig. 2F,G). Thus, FOXP1 SUMOylation specifically recruits Ctbp1 and reduced Ctbp1 recruitment presumably 
accounts for the lack of transcriptional repression by FOXP1- K670R.
Depolarisation decreases FOXP1 SUMOylation. Because neuronal maturation, cortical develop-
ment and network formation are largely driven by neuronal activity27, 28 we next examined whether FOXP1 
SUMOylation is regulated by neuronal activity. Depolarising neurons with 55 mM KCl dramatically reduced 
FOXP1 SUMOylation (Fig. 3A). To investigate possible pathways leading to this depolarisation-evoked reduction 
we tested a range of excitatory receptor agonists (Fig. 3B). Only treatment with glutamate and NMDA elicited a 
significant decrease in FOXP1 SUMOylation (Fig. 3B). Indeed, the NMDA receptor (NMDAR) antagonist AP-5 
prevented the glutamate-evoked decrease in FOXP1 SUMOylation (Fig. 3C) whereas AMPA, the metabotropic 
glutamate receptor agonist DHPG, and the neurotrophin BNDF had no significant effect (Fig. 3B), strongly sug-
gesting neuronal activity regulates FOXP1 SUMOylation through NMDARs.
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Figure 1. FOXP1 is SUMOylated at K670. (A) DIV7 cortical neuronal cultures were lysed in buffer with 
or without 2% SDS and immunoblotted with FOXP1 antibody. Under denaturing conditions a prominent 
additional higher molecular weight FOXP1 band was observed. (B) Following lysis in 2% SDS containing 
buffer, the SDS was diluted to 0.1% and FOXP1 immunoprecipitated and incubated with GST, GST-WT-Senp1 
catalytic domain or GST-Senp1-C603S catalytic domain. Immunoblots with FOXP1 antibody (top panel) 
shows the higher Mr band is removed by Senp1 treatment consistent with it being SUMOylated FOXP1. A 
high exposure (top left panel) of the input shows the presence of the modified-FOXP1. Lower panel shows 
equal levels of purified GST-SENP proteins by coomassie staining. (C) Immunoprecipitation was performed 
as in B, using a SUMO-1 antibody, followed by immunoblotting with either FOXP1 (upper panel) or SUMO1 
(lower panel) antibodies. SUMO1-modified FOXP1 corresponds to the high Mr band in the input. Note the 
enrichment of SUMO1-ylated proteins (seen as a smear) in the IP lane but not the control IgG. (D) Schematic 
of FOXP1 showing the putative SUMOylated lysine. TRD, transcriptional repression domain; LZ, leucine 
zipper; FOX, FOX homolgy domain; NLS, nuclear localisation signal. (E) FOXP1 is SUMOylated at lysine 670. 
HEK293T cells were transfected with either TAP-FOXP1-WT or the mutant TAP-FOXP1-K670R, lysed in 
buffer containing NEM, to inhibit SUMO proteases, and precipitated using strepavidin beads before subsequent 
immunoblotting with anti-SUMO1 (top panel) or anti-SBP (lower panel) antibodies.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 877  | DOI:10.1038/s41598-017-00707-6
Figure 2. SUMOylation of FOXP1 regulates transcriptional repression and co-repressor binding. (A) SV40-
driven luciferase was transfected into HEK293T cells along with either empty TAP vector, TAP-FOXP1-WT 
or TAP-FOXP1-K670R. Firefly luciferase activities were measured and normalised to Renilla lucifierease 
48 hrs after transfection. Student’s t-test, n = 4, **p < 0.01 Note equal expression of TAP-tagged WT or K670R 
mutant in HEK293T cells (upper panels). (B) HEK293T cells were transfected with either TAP-FOXP1-WT 
or TAP-FOXP1-K670R, fractionated into cytosolic (C) or nuclear fractions (N) and immunoblotted. No 
differences were observed indicating that SUMOylation does not regulate nuclear localisation of FOXP1. (C) 
Empty TAP vector, TAP-FOXP1-WT or TAP-FOXP1-K670R were cotransfected into HEK293T cells with GFP-
FOXP1. The cells were lysed, TAP-FOXP1 variants precipitated with strepavidin beads, and immunoblotted 
revealing that SUMOylation does not affect FOXP1-dimerization. Lower panel shows equal expression levels 
of GFP-WT-FOXP1 across conditions. (D) TAP-FOXP1 was expressed in HEK293T cells, precipitated using 
strepavidin beads and resolved by SDS-PAGE followed by silver staining. Gel slices containing novel bands 
compared to control empty vector pulldowns (not shown), were trypsinised and proteins identified using 
Orbitrap mass spectrometery. (E) Cortical neuronal cultures (DIV 7) were lysed and immunoprecipitated 
with anti-Ctbp1 antibodies before being resolved using SDS-PAGE and immunoblotted as indicated. (F) 
SUMOylation of FOXP1 modulates Ctbp1 corepressor binding. Bacterially-purified SUMOylated GST-FOXP1 
was bound to glutathione sepharose beads in the presence or absence of the Senp1-catalytic domain to mediate 
deSUMOylation. DeSUMOylated GST-FOXP1 is observed as a single band in the lower panel at around 
130 KDa compared to the larger SUMOylated GST-FOXP1 bands (Lower panel). The beads were then incubated 
with lysates from cultured cortical neurons. Samples were resolved by SDS-PAGE and blotted for Ctbp1 or 
SMRT. (G) Quantification of (F) is shown as relative Ctbp1 binding to FOXP1. Student’s t-test, n = 3, *p < 0.05.
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Figure 3. Activity-dependent regulation of FOXP1 SUMOylation. (A) Cultured cortical neurons (DIV7) 
were depolarised for 30 min with KCl in ACSF, lysed in sample buffer and resolved by SDS-PAGE followed 
by immunoblotting with the indicated antibodies. Student’s t-test, n = 4, **p < 0.01. (B) Cortical neurons 
were treated with the indicated drugs, lysed in sample buffer and samples resolved by SDS-PAGE and 
immunoblotting. NMDA receptor activation decreases FOXP1 SUMOylation. Note the lower exposure in 
the middle panel indicates unchanged expression levels of unmodified FOXP1. Student’s t-test and Welch 
correction, n = 5 **p < 0.001. (C) Calcium entry through NMDARs and L-type calcium channels reduces 
FOXP1 SUMOylation. Cultures were pre-treated with the NMDAR antagonist AP5, the L-type calcium channel 
blocker nimodipine or EGTA to chelate extracellular Ca2+ prior to glutamate stimulation. Data normalised to 
no glutamate, DMSO control. ANOVA, n = 5, **p < 0.01, *p < 0.05.
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A major feature of NMDARs is that they gate Ca2+ so we tested if extracellular Ca2+ is required for the decrease 
in FOXP1 SUMOylation using the chelator EGTA. Consistent with a signalling pathway involving the influx of 
extracellular Ca2+ through NMDARs leading to nuclear changes29, EGTA prevented the glutamate-mediated 
decrease in FOXP1 SUMOylation (Fig. 3C). The L-type calcium channel inhibitor nimodipine also reduced 
the glutamate-mediated reduction in FOXP1 SUMOylation, albeit to a lesser extent than AP-5 (Fig. 3C). 
Furthermore, in line with minimal Ctbp1 binding to non-SUMOylated FOXP1 (Fig. 2F), glutamate stimulation 
also reduced the Ctbp1-FOXP1 interaction (Fig. 4A,B) providing a mechanistic link between neuronal activity 
and FOXP1-mediated transcriptional repression. Interestingly, glutamate stimulation also caused a decrease in 
CtBP1 binding to HDAC2 but not to LSD1 (Fig. 4C,D), suggesting neuronal activity can result in a partial dis-
assembly of co-repressor complexes in addition to regulating FOXP1 recruitment. Taken together, these results 
suggest that FOXP1-SUMOylation is highly regulated by activity-dependent signalling pathways that impact on 
gene-regulatory pathways involved in neuronal morphogenesis29.
FOXP1 expression is developmentally regulated. Since the reported phenotypes of FOXP1 mutations 
are largely associated with neurodevelopmental defects10 we investigated the profile of FOXP1 expression in rat 
cortex (Fig. 5A). FOXP1 is highly expressed at E18 and up to postnatal day 7 but declines rapidly thereafter, is 
only weakly expressed at P14 and is absent in adult brain. This developmental profile corresponds to the period of 
intense neuronal maturation that drives neuronal network formation30.
FOXP1 SUMOylation is essential for normal dendrite development. To determine how FOXP1 
SUMOylation in cortical neurons affects differentiation, we used virally-expressed shRNAs to ablate endogenous 
Figure 4. Activity-dependent modulation of FOXP1 recruitment to CtBP1 co-repressor complexes. (A) 
Glutamate receptor activation inhibits FOXP1 binding to Ctbp1. Co-immunoprecipitation of Ctbp1 complex 
and FOXP1 following glutamate stimulation of cultured cortical neurons was preceded by a fixation step 
using PFA to prevent deSUMOylation followed by immunoblotting with FOXP1, Ctbp1, LSD1 and HDAC2 
antibodies. (B) Quantification of FOXP1 binding as shown in (A) shows marked reduction in the Ctbp1-FOXP1 
interaction. Student’s t-test, n = 3, *p < 0.05. (C) Histogram of LSD1 binding as shown in (A) shows no-change 
in the Ctbp1-LSD1 interaction. (D) Quantification of HDAC2 binding as shown in (A) shows a decrease in the 
Ctbp1-HDAC2 interaction. Student’s t-test, n = 3, *p < 0.05.
www.nature.com/scientificreports/
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Figure 5. SUMOylation of FOXP1 regulates dendritic outgrowth and length. (A) Expression of FOXP1 peaks 
during early development. Non-denaturing lysates of either embryonic or postnatal brain cortices were analysed 
by SDS-PAGE and immunoblotting. (B) Cortical neurons lentivirally-infected with the indicated knockdown 
or knockdown plus FOXP1-WT or FOXP1-K670R rescue constructs at DIV1 were cultured for a further 7 
days and then lysed in sample buffer and resolved by immunoblotting. (C) SUMOylation of FOXP1 is required 
for dendritc outgrowth. DIV1 cultured cortical neurons were transfected with constructs expressing either 
www.nature.com/scientificreports/
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FOXP1 and replace it with shRNA-insensitive FOXP1-WT or FOXP1-K670R. As proof of concept, we infected 
cortical neurons at DIV1 and analysed them at DIV7. As anticipated, FOXP1 knockdown at DIV1 markedly 
reduced levels of endogenous FOXP1 (Fig. 5B). Furthermore, at DIV7 endogenous and recombinantly expressed 
FOXP1-WT were robustly SUMOylated but there was no detectable SUMOylation of FOXP1-K670R (Fig. 5B).
To examine the role of FOXP1 SUMOylation on neuronal morphology, we next transfected DIV1 cortical 
neurons with constructs expressing either scrambled shRNA, FOXP1 knockdown, or FOXP1 knockdown with 
WT or K670R ‘rescue’ and assessed neurons at DIV8. FOXP1 ablation caused severely stunted dendritic devel-
opment and reduced dendritic length by ~50% (Fig. 5C). Replacement with FOXP1-WT rescued this phenotype 
but non-SUMOylatable FOXP1-K670R did not (Fig. 5C,D). FOXP1 knockdown also reduced the number of 
dendritic tips by ~50% (Fig. 5E), suggesting a role for FOXP1 in branching of the dendritic tree. Again, this phe-
notype was rescued by WT-FOXP1 but by the K670R mutant. Total axonal length was unaffected in any of the 
conditions (Fig. 5F). These data demonstrate a specific role for tonic SUMOylation of FOXP1 in normal cortical 
neuron development and morphogenesis.
Although there are likely to be many neuronal-specific transcriptional targets of FOXP1 repression responsi-
ble for regulating dendrite morphogenesis, one validated target is the candidate autism gene CNTNAP231. Since 
Cntnap2 plays a key role in dendrite arborization32, we tested whether FOXP1-SUMOylation is required for efficient 
transcriptional repression of the rat Cntnap2 gene. FOXP1 knockdown caused a marked increase in CNTNAP2 
expression, presumably by relieving repression of its transcription (Fig. 5G). Expression of shRNA-resistant WT 
FOXP1 in the knockdown cells returned Cntnap2 to near baseline levels. However, consistent with SUMOylation 
being required for efficient transcriptional repression, replacement with non-SUMOylatable FOXP1-K670R did not 
reduce the increased levels of expression observed in the FOXP1 knockdown cells.
Discussion
Here we show that SUMOylation of the transcriptional repressor FOXP1 is a key regulator of normal dendritic 
outgrowth and complexity in the brain. In agreement with a recent study11 we find that FOXP1 expression in 
rat cortex is developmentally regulated and FOXP1 is maximally expressed when neurons are maturing and 
forming neuronal networks. FOXP1 SUMOylation acts as an interaction platform for recruitment of the CtBP1 
co-repressor complex and is regulated by activity-dependent Ca2+ signalling. This fits well with the established 
role of SUMO modification in regulating the protein-protein interactions of transcription factors33 and uncov-
ers a novel mechanism of neuronal activity ‘fine-tuning’ transcriptional co-repressor recruitment through 
SUMOylation. Moreover, it has been proposed that spatially confined proteins can be simultaneously and syn-
ergistically SUMOylated to facilitate protein complex formation34. Consistent with this concept the FOXP1 
‘co-repressor’ components CtBP135 and HDAC1/236 are targets for SUMOylation. Furthermore, neuronal activity 
results in the loss of HDAC2 from the CtBP1 corepressor complex, suggesting that SUMOylation may also par-
ticipate in the regulation of core corepressor assembly.
Our finding that tonic FOXP1 SUMOylation selectively regulates dendrites but not axons suggests that active 
FOXP1 is part of the cell-intrinsic transcriptional program that controls dendritic specification in the cortex37. 
This is also consistent with SUMOylation playing a general role in dendritic morphogensis38, 39. Activity regulates 
both positive and negative mediators of dendritic complexity in neurons40 and the activity-dependent signal-
ling that modulates FOXP1 SUMOylation provides further evidence that FOXP1 is both integral to, and tightly 
regulated during, neuronal development. In apparent contrast, however, a recent study using FOXP1 knockout 
mice reported that FOXP1 regulates axonal length and neuronal migration in the cortex11. While still unclear, 
reasons for this discrepancy may involve differences between the effects of chronic knockout in mice and acute 
shRNA-mediated knockdown of FOXP1 in rat neurons.
We propose a model of the activity-dependent regulation of FOXP1 function during dendrite development 
(Fig. 6). SUMOylated FOXP1 acts as a crucial transcriptional regulator that tonically represses key target genes 
to control the normal developmental maturation of neurons. How then can activity-dependent signals also lead 
to dendritic growth? We suggest that temporally controlled deSUMOylation of FOXP1 can direct dendritic out-
growth to appropriately integrate activity-dependent cues into programs of perinatal gene expression that shape 
and mature dendritic arborisation.
Although FOXP1 is only highly expressed around birth, the constant modulation of FOXP1 SUMOylation by 
activity-dependent signals will facilitate the conditions for shaping the dendritic tree and establishing the genetic 
landscape required for neuronal maturation, prior to loss of FOXP1 expression and set the scene for subsequent 
refinement of arborisation by other mechanisms later in development.
scrambled shRNA, FOXP1 shRNA or FOXP1 shRNA plus FOXP1-WT or FOXP1-K670R rescue and prepared 
for imaging at DIV8. In all images of neuronal morphology, blue arrows and black arrowheads indicate 
dendrites and axons, respectively. Scale bar, 10 μm. (D) Knockdown of FOXP1 significantly shortens dendritic 
length. FOXP1-WT but not the SUMOylation-deficient FOXP1-K670R rescued the dendritic phenotype. 312 
neurons were analysed using the neuron J plugin for Image J. ANOVA, **p < 0.01, *p < 0.05. (E) Knockdown of 
FOXP1 significantly reduces the total number of dendritic tips. FOXP1-WT but not the SUMOylation-deficient 
FOXP1-K670R rescued the deficit in dendritic tip number. 302 neurons were analysed using the neuron J 
plugin for image J. ANOVA, **p < 0.01. (F) Axonal length was not significantly different between any FOXP1 
knockdown or rescue with either WT-FOXP1 or the SUMOylation-deficient K670R FOXP1 mutant. (G) 
Knockdown of FOXP1 significantly increases Cntnap2 expression. DIV1 cultures were infected as in C, followed 
by RNA extraction and RT-PCR analysis. FOXP1-WT but not the SUMOylation-deficient FOXP1-K670R 
rescued Cntnap2 transcript levels back to control levels. ANOVA, n = 4, **p < 0.01, *p < 0.05.
www.nature.com/scientificreports/
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Given that SUMOylated FOXP1 must, in part, control the expression of genes that are required for normal 
dendritic morphogenesis a key, as yet unanswered, question is what the identity of these genes might be? The 
autism-linked, neurexin-like adhesion molecule CNTNAP2 (also known as CASPR2)41 is a strong candidate. 
CNTNAP2 is required for dendritic arborisation32 and spine development42, 43. Both FOXP1 and FOXP2 repress 
CNTNAP2 expression31, 44 and in knockdown rescue experiments we show that non-SUMOylatable FOXP1 
fails to repress Cntnap2 expression (Fig. 5G). Together, these data suggest that SUMOylated FOXP1 normally 
represses expression of Cntnap2 but that temporally enhanced expression mediated by FOXP1 deSUMOylation 
may be required to facilitate appropriate dendritic growth and arborisation during the perinatal period. Clues 
to the other targets mediating the neuronal function of FOXP1 could come from FOXP2, since these repressors 
heterodimerise20 and can share promoter occupancy45. FOXP2 regulates a network of genes implicated in neu-
rite outgrowth, including genes directly involved in dendrite formation in the cortex, such as the Eph receptor 
EphrB2, and indirectly, like the transcription factor Lmo446.
It is important to note that FOXP1 also functions as a transcriptional repressor outside the nervous system. 
For example, in the immune system FOXP1 is involved in naïve T-cell quiescence47 and B-cell development48. 
Interestingly, stimulation of T-cell antigen receptor signalling regulates the SUMOylation of the kinase PCKθ49 
and the transcription factor IRF450. This raises the intriguing possibility that TCR signalling in the immune sys-
tem could be analogous to NMDAR signalling in the nervous system and regulate the SUMOylation of FOXP1 to 
control its binding to CtBP1 and transcriptional repression.
Together our data suggest SUMO-dependent regulation of FOXP1 is a key component in gene expression 
programs during activity-dependent remodelling of neuronal architecture and provide new mechanistic insight 
into how dysregulation of human FOXP proteins can lead to neurodevelopmental disorders such as language 
impairment and autism spectrum disorders.
Methods
Buffers. Modified RIPA: 25 mM Tris-HCl, ph 7.5, 125 mM NaCl, 1% NP40, 0.5% sodium deoxycholate and 
1 mM EDTA.
SDS-containing buffer: 1 part SDS sample buffer: 5% SDS, 150 mM Tris-HCl, pH 6.7, 30% glycerol plus 3 parts 
of RIPA buffer: 25 mM Tris pH 8.2, 50 mM NaCl, 0.5% NP40, 0.5% sodium deoxycholate and 0.1% SDS.
DNA constructs. A rat-specific shRNA sequence against FOXP1 (5′-TGCGAGTAGAGAACGTTAAA-3′) 
was cloned into the lentiviral vector pXLG351. shRNA-resistant FOXP1 contained three silent base mismatches in 
the ORF cloned from E18 rat brain cDNA using the primer: 5-CGA GTG GAA AAC GTT AAA-3′. The result-
ing ORF was inserted into the same pXLG3 vector, where a separate expression cassette driven by the ubiquitin 
Figure 6. SUMOylation of FOXP1 regulates dendritic outgrowth and length. Taken together, our data suggests 
a model in which activity-dependent signals trigger the dynamic reduction of FOXP1 SUMOylation, as well as 
co-repressor recruitment, thereby modulating its function as a crucial transcriptional regulator that tonically 
controls the normal developmental maturation of neurons. We believe timely deSUMOylation of FOXP1 allows 
neurons to appropriately convert such activity-dependent cues into programs of gene-expression that finely 
‘shape’ and ‘mature’ the dendritic tree (as opposed to continual growth) to aid and guide the structural and 
functional maturation of neuronal circuits.
www.nature.com/scientificreports/
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promoter was inserted to express GFP-IRES-FOXP1. SUMOylation-deficient FOXP1-K670R rescue was gener-
ated by site-directed mutagenesis. These constructs were also sub-cloned into the TAP-tagging vector pNTAP-B 
(Agilent), which tags proteins with both streptavidin-binding peptide (SBP) and calmodulin-binding peptide 
(CBP) tags to generate TAP-FOXP1, as well as pGEX4T1 (Amersham) and pEGFP-C2 (Clontech).
Antibodies. Anti-FOXP1 (D35D10, Cell Signaling), anti-EGFR (ab98133, Abcam), anti-Lamin B (Santa 
Cruz), anti-RhoGDI (EPR3773, Abcam), anti-HDAC2 (3F3, Cell Signaling), anti-HDAC4 (4A3, Cell Signaling), 
anti-LSD1 (Cell Signaling), anti-Ctbp1 (EMD millipore), anti-SMRT (EMD millipore), anti-GFP (ab13970, 
abcam), anti-MAP2 (Sigma), anti-GAPDH (Abcam), and anti-SBP (EMD millipore).
Lentivirus production. Lentiviral particles were produced in HEK293T cells maintained in DMEM (D5796, 
Sigma) supplemented with 10% (v/v) fetal bovine serum (F7524, Sigma) as previously described51. After harvest-
ing, DIV1 rat cultured cortical neurons were incubated with lentiviral particles for 6 hr followed by media change 
into Neurobasal feeding medium (Thermo Fisher)
Mass spectrometry. HEK293T cells were transfected with either empty TAP vector or TAP-FOXP1 and 
lysed 48 hr after transfection in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCL, 0.5% NP-40 and Roche 
protease inhibitor cocktail) before pull-down of the TAP tag using strepavidin beads (Sigma) for 1 hr. The samples 
were resolved on 4–15% precast gels (BioRad), silver stained and bands specific to the TAP-FOXP1 pulldown 
only were subjected to liquid chromatography-tandem mass spectrometry analysis on an Orbitrap Velos mass 
spectrometer (Thermo Fisher) to identify interacting-proteins.
Bacterial SUMOylation. The bacterial SUMOylation assay was performed as described previously25 and the 
resulting SUMOylated GST-FOXP1 bound to glutathione beads was incubated in equal amounts with or without 
purified his6-Senp1 catalytic domain to promote deSUMOylation. Immobilised SUMOylated or de-SUMOylated 
GST-FOXP1 was then incubated with cortical neuronal lysates for 1 hr, followed by extensive washing and subse-
quent analysis by SDS-PAGE and western blotting.
Dimerisation assay. HEK293T cells were transfected with either: empty TAP vector, TAP-FOXP1-WT or 
TAP-FOXP1-K670R along with GFP-FOXP1. Cells were harvested in lysis buffer (0.5% TX-100, 150 mM NaCl, 
25 mM Tris pH 7.5 and Roche protease inhibitors) and cleared lysates incubated with strepavidin beads for 1 hr. 
Samples were washed extensively in lysis buffer and processed for SDS-PAGE and western blotting.
Cellular fractionation. HEK293T cells transfected with either TAP-WT-FOXP1 or TAP-FOXP1-K670R 
were fractionated 48 hr after transfection into cytosolic and nuclear fractions using a Cell Fractionation Kit (Cell 
Signaling) as per the manufacturer’s instructions.
Transfection and immunocytochemistry. Primary cortical neurons were prepared from Wistar rat E18 
embryos as previously described52, transfected at DIV1 with Lipofectamine 2000 (ThemroFisher) and fixed 6–7 
days later in 4% PFA, before processing for immunocytochemistry and staining.
SUMOylation analysis. Cultured cortical neurons were lysed in ‘modified’ RIPA without SDS or in 
SDS-containing buffer containing Roche protease inhibitors. Lysates were incubated on ice for 20 mins, cleared 
by centrifugation at 13,000 rpm for 10 min, and analysed by SDS-PAGE and western blotting.
Immunoprecipitation assays. Cells lysed in SDS-sample buffer were diluted 10x with PBS containing 0.5% 
NP40. After clearing, supernatants were incubated with either non-immune IgG, anti-FOXP1 or anti-SUMO1 
antibodies for 2 hours, then with Protein A/G beads, washed and processed for western blotting.
Senp1-cleavage assay. Washed beads were incubated with either purified free-GST, GST-Senp1-WT or 
GST-Senp1-C603S proteins in PBS, washed and western blotted.
Luciferase assay. HEK293 cells were transfected with 50 ng of pGL3-promoter construct (Promega), 50 ng 
of pRL-TK renilla luciferase construct (Promega) and either empty pNTAP-B vector, TAP-tagged FOXP1-WT or 
TAP-tagged FOXP1-K670R. Cells were lysed 48 hr after transfection and both firefly and renilla luciferase activity 
quantified using the Dual Luciferase Reporter Assay System (Promega).
RT-PCR. Cortical neurons were infected with the indicated lentiviruses for shRNA-mediated knock-
down and rescue, followed by lysis and RNA extraction using the RNAeasy kit (Qiagen) as per manufactur-
ers instructions. After subsequent cDNA synthesis, RT-PCR was carried out using standard protocols and 
PCR cycles were optimised for each reaction so as to be within a linear range. Primers used were as follows: 
Foxp1 (5′-TGCGAGTAGAGAACGTTAAA-3′), CNTNAP2 (CAGCGGAGACACAAACACAT), gapdh 
(5′-AATCCCATCACCATCTTCCA-3′).
Morphometry of cortical neurons. Images of individual transfected cortical neurons were captured on 
a Leica SP5 confocal microscope at 20x magnification and at high resolution (1024 × 1024). Acquired images 
were analysed in ImageJ using the NeuronJ plugin. Two way ANOVA was used followed by Bonferroni multiple 
comparisons test.
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